Mallinckrodt Signs its First RNAi Deal with Silence Therapeutics
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 8 (Table of Contents)
Published: 1 Aug-2019
DOI: 10.3833/pdr.v2019.i8.2444 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Joining the likes of Janssen, Eli Lilly and Regeneron, Mallinckrodt has now ventured into the field of RNAi therapeutics with a potential US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS